vs
ClearSign Technologies Corp（CLIR）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是ClearSign Technologies Corp的17.7倍（$65.1M vs $3.7M）。MESA LABORATORIES INC净利率更高（5.6% vs -8.5%，领先14.0%）。ClearSign Technologies Corp同比增速更快（522.2% vs 3.6%）。过去两年ClearSign Technologies Corp的营收复合增速更高（82.5% vs 5.1%）
ClearSign Technologies是一家总部位于美国的科技企业，核心业务为排放控制技术的研发，致力于通过技术创新帮助工业领域降低污染物排放，助力实现更环保的生产运营。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CLIR vs MLAB — 直观对比
营收规模更大
MLAB
是对方的17.7倍
$3.7M
营收增速更快
CLIR
高出518.6%
3.6%
净利率更高
MLAB
高出14.0%
-8.5%
两年增速更快
CLIR
近两年复合增速
5.1%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $3.7M | $65.1M |
| 净利润 | $-311.0K | $3.6M |
| 毛利率 | 21.9% | 64.2% |
| 营业利润率 | -22.5% | 12.2% |
| 净利率 | -8.5% | 5.6% |
| 营收同比 | 522.2% | 3.6% |
| 净利润同比 | 73.3% | 316.6% |
| 每股收益（稀释后） | $-0.06 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLIRMLAB
| Q4 25 | $3.7M | $65.1M | ||
| Q3 25 | $1.0M | $60.7M | ||
| Q2 25 | $133.0K | $59.5M | ||
| Q1 25 | $401.0K | $62.1M | ||
| Q4 24 | $590.0K | $62.8M | ||
| Q3 24 | $1.9M | $57.8M | ||
| Q2 24 | $45.0K | $58.2M | ||
| Q1 24 | $1.1M | $58.9M |
净利润CLIRMLAB
| Q4 25 | $-311.0K | $3.6M | ||
| Q3 25 | $-1.4M | $2.5M | ||
| Q2 25 | $-1.7M | $4.7M | ||
| Q1 25 | $-2.1M | $-7.1M | ||
| Q4 24 | $-1.2M | $-1.7M | ||
| Q3 24 | $-1.2M | $3.4M | ||
| Q2 24 | $-1.9M | $3.4M | ||
| Q1 24 | $-1.1M | $-254.6M |
毛利率CLIRMLAB
| Q4 25 | 21.9% | 64.2% | ||
| Q3 25 | 35.8% | 61.5% | ||
| Q2 25 | 41.4% | 62.0% | ||
| Q1 25 | 48.9% | 61.8% | ||
| Q4 24 | 14.9% | 63.3% | ||
| Q3 24 | 29.6% | 61.3% | ||
| Q2 24 | 93.3% | 64.0% | ||
| Q1 24 | 39.7% | 62.1% |
营业利润率CLIRMLAB
| Q4 25 | -22.5% | 12.2% | ||
| Q3 25 | -170.1% | 7.8% | ||
| Q2 25 | -1382.0% | 5.1% | ||
| Q1 25 | -562.8% | 2.4% | ||
| Q4 24 | -282.4% | 9.2% | ||
| Q3 24 | -77.1% | 6.1% | ||
| Q2 24 | -4748.9% | 9.6% | ||
| Q1 24 | -113.6% | -460.6% |
净利率CLIRMLAB
| Q4 25 | -8.5% | 5.6% | ||
| Q3 25 | -138.9% | 4.1% | ||
| Q2 25 | -1263.2% | 8.0% | ||
| Q1 25 | -517.7% | -11.4% | ||
| Q4 24 | -197.3% | -2.7% | ||
| Q3 24 | -62.1% | 5.9% | ||
| Q2 24 | -4160.0% | 5.8% | ||
| Q1 24 | -100.5% | -432.2% |
每股收益（稀释后）CLIRMLAB
| Q4 25 | $-0.06 | $0.65 | ||
| Q3 25 | $-0.26 | $0.45 | ||
| Q2 25 | $-0.30 | $0.85 | ||
| Q1 25 | $-0.37 | $-1.30 | ||
| Q4 24 | $-0.18 | $-0.31 | ||
| Q3 24 | $-0.20 | $0.63 | ||
| Q2 24 | $-0.40 | $0.62 | ||
| Q1 24 | $-0.30 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.2M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $9.5M | $186.7M |
| 总资产 | $12.2M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CLIRMLAB
| Q4 25 | $9.2M | $29.0M | ||
| Q3 25 | $10.5M | $20.4M | ||
| Q2 25 | $12.3M | $21.3M | ||
| Q1 25 | $12.9M | $27.3M | ||
| Q4 24 | $14.0M | $27.3M | ||
| Q3 24 | $14.5M | $24.3M | ||
| Q2 24 | $16.0M | $28.5M | ||
| Q1 24 | $4.6M | $28.2M |
总债务CLIRMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益CLIRMLAB
| Q4 25 | $9.5M | $186.7M | ||
| Q3 25 | $9.1M | $178.5M | ||
| Q2 25 | $10.4M | $172.5M | ||
| Q1 25 | $12.0M | $159.8M | ||
| Q4 24 | $13.8M | $155.2M | ||
| Q3 24 | $14.8M | $161.5M | ||
| Q2 24 | $15.9M | $150.7M | ||
| Q1 24 | $4.5M | $145.4M |
总资产CLIRMLAB
| Q4 25 | $12.2M | $434.8M | ||
| Q3 25 | $12.7M | $430.4M | ||
| Q2 25 | $14.2M | $435.7M | ||
| Q1 25 | $14.5M | $433.3M | ||
| Q4 24 | $16.3M | $433.3M | ||
| Q3 24 | $17.1M | $454.1M | ||
| Q2 24 | $17.8M | $440.4M | ||
| Q1 24 | $6.6M | $446.8M |
负债/权益比CLIRMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流CLIRMLAB
| Q4 25 | $-1.3M | $18.8M | ||
| Q3 25 | $-1.8M | $8.2M | ||
| Q2 25 | $-511.0K | $1.9M | ||
| Q1 25 | $-1.1M | $12.7M | ||
| Q4 24 | $-415.0K | $18.1M | ||
| Q3 24 | $-1.4M | $5.3M | ||
| Q2 24 | $-1.5M | $10.7M | ||
| Q1 24 | $-1.0M | $12.9M |
自由现金流CLIRMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | $-1.1M | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率CLIRMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | -278.1% | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度CLIRMLAB
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率CLIRMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLIR
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
